El-Kharashy Ghada, Gowily Ahmed, Okda Tarek, Houssen Maha
Department of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour 22511, Egypt.
Department of Oncology Medicine, Faculty of Medicine, Alexandria University, Alexandria 21111, Egypt.
Mol Clin Oncol. 2021 Feb;14(2):38. doi: 10.3892/mco.2020.2200. Epub 2020 Dec 24.
Soluble Toll-like receptor (sTLR) 2 and 4 are endogenous negative regulators of TLR2 and TLR4 signaling. Therefore, the present study aimed to determine the serum levels of sTLR2 and 4, and to investigate the association between their levels and the clinicopathological parameters of patients with breast cancer. A total of 100 female patients with breast cancer (50 non-metastatic and 50 metastatic), as well as 50 healthy control volunteers were enrolled in the present study, and serum levels of sTLR2 and 4 were determined by ELISA. A significant increase in serum sTLR2 was detected in patients with non-metastatic (2,258.2±1,832.44 pg/ml) and metastatic (5,997.4±8,585.23 pg/ml) breast cancer, compared with the control group (1,106.8± 99.93 pg/ml; P=0.0001). A significant increase in serum sTLR4 was also detected in patients with both non-metastatic (1,945.2±1,709.53 pg/ml) and metastatic breast cancer (7,800.1±13,041.28 pg/ml), compared with the control group (1,106.8±108.32 pg/ml; P=0.0001). Furthermore, a positive correlation was observed between the levels of serum sTLR4 and 2 and clinicopathological parameters, such as progesterone receptor and estrogen receptor expression. In conclusion, sTLR2 and sTLR4 may be potential biomarkers of breast cancer susceptibility.
可溶性Toll样受体（sTLR）2和4是TLR2和TLR4信号通路的内源性负调节因子。因此，本研究旨在测定血清中sTLR2和4的水平，并探讨其水平与乳腺癌患者临床病理参数之间的关联。本研究共纳入100例女性乳腺癌患者（50例非转移性和50例转移性）以及50名健康对照志愿者，采用酶联免疫吸附测定法（ELISA）测定血清中sTLR2和4的水平。与对照组（1,106.8±99.93 pg/ml；P = 0.0001）相比，非转移性乳腺癌患者（2,258.2±1,832.44 pg/ml）和转移性乳腺癌患者（5,997.4±8,585.23 pg/ml）血清sTLR2水平显著升高。与对照组（1,106.8±108.32 pg/ml；P = 0.0001）相比，非转移性乳腺癌患者（1,945.2±1,709.53 pg/ml）和转移性乳腺癌患者（7,800.1±13,041.28 pg/ml）血清sTLR4水平也显著升高。此外，血清sTLR4和2的水平与孕酮受体和雌激素受体表达等临床病理参数之间存在正相关。总之，sTLR2和sTLR4可能是乳腺癌易感性的潜在生物标志物。
